Ipsen - Octobre 2026 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

Ipsen reported strong financial performance in the first nine months of 2026 with total sales growth of 24.6% at constant exchange rates and upgraded full-year guidance. The company's IQIRVO® treatment demonstrated positive late-breaking data from the ELSPIRE study, with 85.3% of patients achieving ALP normalization in primary biliary cholangitis (PBC), results to be presented at The Liver Meeting® 2026.